Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma.
Kropff M, Bisping G, Schuck E, Liebisch P, Lang N, Hentrich M, Dechow T, Kröger N, Salwender H, Metzner B, Sezer O, Engelhardt M, Wolf HH, Einsele H, Volpert S, Heinecke A, Berdel WE, Kienast J; Deutsche Studiengruppe Multiples Myelom,.
Kropff M, et al. Among authors: einsele h.
Br J Haematol. 2007 Aug;138(3):330-7. doi: 10.1111/j.1365-2141.2007.06656.x.
Br J Haematol. 2007.
PMID: 17614819
Free article.
Clinical Trial.